How Nestlé is using next-gen tech to target GLP-1 consumers
Nestlé is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity,…
Nestlé targets GLP-1 users with new nutrition and beauty-from-within products
THE WHAT? Nestlé is developing products specifically for consumers using GLP-1 weight-loss drugs, targeting nutritional and appearance-related effects…
Nestlé Is No Longer Afraid of Ozempic and Other GLP-1 Drugs—Now It Wants to Sell Food to the People Who Use Them
During the early years of the GLP-1 drug revolution, the food industry watched Ozempic almost like a storm…
Samsung Biologics Acquires Swiss CDMO for approximately $1.8 Billion, Making a Major Push into the Obesity Drug Market — BigGo Finance
Samsung Biologics (207940) is investing approximately 2.7 trillion won (approximately $1.8 billion) to acquire PolyPeptide Group, a global…
Samsung Biologics Acquires Swiss PolyPeptide Group for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance
Samsung Biologics is making a blockbuster acquisition of PolyPeptide Group AG, a Swiss peptide contract development and manufacturing…
Samsung Biologics Bets $1.8 Billion on ‘K-Obesity Drug’ Play with Swiss PolyPeptide Acquisition — BigGo Finance
Samsung Biologics has thrown its hat into the rapidly growing global obesity treatment market, committing 2.7 trillion won…
Samsung Biologics Acquires Swiss Peptide CDMO PolyPeptide Group for approximately $1.8 Billion — BigGo Finance
Samsung Biologics (207940) has placed a major bet on capturing the global peptide contract development and manufacturing organization…
Samsung Biologics to Acquire Swiss Peptide CDMO for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance
Samsung Biologics (207940.KS) announced on the 20th that it will acquire PolyPeptide Group, a global peptide contract development…
Kane County to cut weight-loss drugs from insurance plans
As a means to reduce future spending, Kane County is removing coverage of weight-loss drugs from its employees’…
Takeda, Innovent-Lilly, Roche—Fierce Pharma Asia
Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a…
Pfizer, Amgen and Roche race to cut GLP-1 obesity shots to 4–13 a year
Next-generation obesity drugs to follow Wegovy and Mounjaro are under development. Provided by Getty Images Bank As obesity…
What’s next for Roche’s expensive obesity pipeline?
It’s been less than two years since Roche dove into the obesity space with its $2.7 billion acquisition…